Terbinafine-Resistant Dermatophytes Isolated in Japan.

Medical mycology journal Pub Date : 2025-01-01 DOI:10.3314/mmj.24-00020

Honoka Nojo, Junichiro Hiruma, Hiromitsu Noguchi, Tatsuya Shimizu, Masataro Hiruma, Kazutoshi Harada, Koichi Makimura, Rui Kano

{"title":"Terbinafine-Resistant Dermatophytes Isolated in Japan.","authors":"Honoka Nojo, Junichiro Hiruma, Hiromitsu Noguchi, Tatsuya Shimizu, Masataro Hiruma, Kazutoshi Harada, Koichi Makimura, Rui Kano","doi":"10.3314/mmj.24-00020","DOIUrl":null,"url":null,"abstract":"<p><p>An epidemiological study of terbinafine (TBF)-resistant dermatophytes was conducted in 2023 as a follow-up to our 2020 and 2022 surveys. Dermatophytes were isolated in 2023 from the same dermatology clinics in Tokyo, Saitama, Shizuoka, and Kumamoto, Japan, as in the previous studies. In total, 311 isolates (122 Trichophyton interdigitale isolates, 1 Trichophyton indotineae isolate, and 188 Trichophyton rubrum isolates) were obtained from 311 human cases of dermatophytosis (195 tinea pedis cases, 54 tinea unguium cases, 28 tinea corporis cases, 27 tinea cruris cases, and 7 tinea manuum cases). Ten strains (1 T. interdigitale strain and 9 T. rubrum strains) were found to be resistant to TBF, and susceptible to efinaconazole, itraconazole, luliconazole, and ravuconazole. The isolation rate of TBF-resistant strains was 2.3% in 2020, 1.4% in 2022, and 3.2% in 2023. We determined the sequences of the squalene epoxidase-encoding gene in 10 TBF-resistant strains, and found that all strains harbored missense and/or deletion mutations. These results indicate that the prevalence of TBF-resistant dermatophytes has increased when compared to the previous studies.</p>","PeriodicalId":520314,"journal":{"name":"Medical mycology journal","volume":"66 1","pages":"11-15"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical mycology journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3314/mmj.24-00020","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

An epidemiological study of terbinafine (TBF)-resistant dermatophytes was conducted in 2023 as a follow-up to our 2020 and 2022 surveys. Dermatophytes were isolated in 2023 from the same dermatology clinics in Tokyo, Saitama, Shizuoka, and Kumamoto, Japan, as in the previous studies. In total, 311 isolates (122 Trichophyton interdigitale isolates, 1 Trichophyton indotineae isolate, and 188 Trichophyton rubrum isolates) were obtained from 311 human cases of dermatophytosis (195 tinea pedis cases, 54 tinea unguium cases, 28 tinea corporis cases, 27 tinea cruris cases, and 7 tinea manuum cases). Ten strains (1 T. interdigitale strain and 9 T. rubrum strains) were found to be resistant to TBF, and susceptible to efinaconazole, itraconazole, luliconazole, and ravuconazole. The isolation rate of TBF-resistant strains was 2.3% in 2020, 1.4% in 2022, and 3.2% in 2023. We determined the sequences of the squalene epoxidase-encoding gene in 10 TBF-resistant strains, and found that all strains harbored missense and/or deletion mutations. These results indicate that the prevalence of TBF-resistant dermatophytes has increased when compared to the previous studies.

查看原文本刊更多论文

日本分离的耐特比萘芬皮肤菌。

作为2020年和2022年调查的后续，2023年进行了一项特比萘芬（TBF）抗性皮肤癣菌的流行病学研究。与先前的研究一样，于2023年从日本东京、埼玉、静冈县和熊本的同一皮肤科诊所分离出皮肤真菌。从311例人类皮肤癣患者（足癣195例、甲癣54例、体癣28例、股癣27例、手癣7例）中共分离出311株分离物（趾间毛癣122株、印癣毛癣1株、红癣毛癣188株）。10株（指间T.株1株，红T.株9株）对TBF耐药，对依非那康唑、伊曲康唑、吕立康唑、拉乌康唑敏感。2020年、2022年和2023年tbf耐药菌株分离率分别为2.3%、1.4%和3.2%。我们测定了10株tbf耐药菌株的角鲨烯环氧化酶编码基因序列，发现所有菌株都存在错义和/或缺失突变。这些结果表明，与以前的研究相比，耐tbf的皮肤真菌的患病率有所增加。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Medical mycology journal

自引率

0.00%

发文量